UBS announced a net profit of $1.4 billion for the second quarter of 2019.Earningsread more
Japan and South Korea are part of a complex and tightly linked supply chain that produces electronic goods such as smartphones and laptops.Technologyread more
Michael Kugelman from the U.S.-based Wilson Center says other issues take precedence in the bilateral dialogue between the United States and Pakistan — namely, Afghanistan and...Asia Politicsread more
Beijing says it can still meet its 2019 growth target of between 6% and 6.5% and continues to roll out stimulus measures to prop up activity. China set a 2019 industrial...China Economyread more
A different oil pricing dynamic has been evolving with new supply calculations based on the U.S. as the world's largest producer.Market Insiderread more
The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Stocks in Asia Pacific edged up on Tuesday, as investors await closely-watched central bank meetings in the coming days.Asia Marketsread more
More than half of Venezuela's 23 states lost power on Monday, according to Reuters witnesses and reports on social media, a blackout the government blamed on an...World Politicsread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
The deal between the White House and Democrats was earlier expected to raise the debt ceiling for two years and permanently end the sequester.Politicsread more
Britain's Antstream is jumping into the cloud gaming battle with a streaming platform for retro titles. And Tencent just backed the company.Technologyread more
Jim Cramer said Friday that he was shocked after Bristol-Myers Squibb announced its lung cancer drug failed in a late-stage study.
Shares of Bristol-Myers dropped more than 17 percent Friday morning while competitors, such as Merck with different versions of the cancer therapy, rose.
The drug, Opdivo, failure comes as a surprise because it has been approved to treat other types of cancer. Lung cancer is the leading cause of cancer death in the United States, according to the Center for Disease Control and Prevention.
"This was the hottest drug in our era, arguably," Cramer told CNBC's "Squawk on the Street. " "I am stunned because the success rate of this drug has been amazing."
He added, peak revenues for the drug could have been around $12 billion to $15 billion.
SunTrust Robinson Humphrey downgraded Bristol-Myers' shares to "neutral" from "buy" after the news.